Monitoring the effect of docetaxel treatment in MCF7 xenografts using multimodal in vivo and ex vivo magnetic resonance methods, histopathology, and gene expression

Translational Oncology

Volumn 3, Issue 4, 2010, Pages 252-263

  Huuse, Else Marie ^a   Jensen, Line Rørstad ^a   Goa, Pål Erik ^a,b   Lundgren, Steinar ^a,b   Anderssen, Endre ^a   Bofin, Anna ^a   Gribbestad, Ingrid Susann ^a   Bathen, Tone Frost ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; DOCETAXEL; SODIUM CHLORIDE;

ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CALCULATION; CELL DEATH; CELL PROLIFERATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG MONITORING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EXTRAVASCULAR FLUID; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MITOSIS; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SENSITIVITY AND SPECIFICITY; THERAPY EFFECT; TUMOR BIOPSY; TUMOR XENOGRAFT;

EID: 77955700216     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09322     Document Type: Article

References (67)

1. Parkin DM, Bray F, Ferlay J, and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55(2), 74-108.
2. Crown J and O'Leary M (2000). The taxanes: an update. Lancet 355(9210), 1176-1178.
3. Moulder S and Hortobagyi GN (2008). Advances in the treatment of breast cancer. Clin Pharmacol Ther 83(1), 26-36.
4. Estevez LG and Gradishar WJ (2004). Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10(10), 3249-3261.
5. Hernandez-Vargas H, Palacios J, and Moreno-Bueno G (2007). Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle 6(7), 780-783.
6. Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, Lundgren S, and Gribbestad IS (2010). Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS. NMR Biomed 23(1), 56-65.
7. Glunde K and Serkova NJ (2006). Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7(7), 1109-1123.
8. Negendank W(1992). Studies of human tumors by MRS: a review. NMR Biomed 5(5), 303-324.
9. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, and Gillies RJ (2007). Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 58(2), 270-280.
10. Glunde K, Jie C, and Bhujwalla ZM (2004). Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64(12), 4270-4276.
11. Glunde K, Ackerstaff E, Mori N, Jacobs MA, and Bhujwalla ZM (2006). Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 3(5), 496-506.
12. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett B, Raghunand N, and Gillies RJ (2009). Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed 22(1), 114-127.
13. Hernandez-Vargas H, Palacios J, and Moreno-Bueno G (2007). Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26(20), 2902-2913.
14. Morse DL, Gray H, Payne CM, and Gillies RJ (2005). Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4(10), 1495-1504.
15. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, and Gillies RJ (1999). Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1(2), 113-117.
16. Kim H, Morgan DE, Zeng H, Grizzle WE, Warram JM, Stockard CR, Wang D, and Zinn KR (2008). Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 248(3), 844-851.
17. Pickles MD, Gibbs P, Lowry M, and Turnbull LW (2006). Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24(7), 843-847.
18. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, et al. (2007). Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25(1), 1-13.
19. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van CM, Collins D, et al. (2009). Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2), 102-125.
20. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, and Schwartz EL (2002). Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 1(13), 1191-1200.
21. Turnbull LW(2009). Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 22(1), 28-39.
22. Tofts PS (1997). Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7(1), 91-101.
23. Hayes C, Padhani AR, and Leach MO (2002). Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15(2), 154-163.
24. Martincich L, Montemurro F, De RG, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, et al. (2004). Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83(1), 67-76.
25. Pickles MD, Lowry M, Manton DJ, Gibbs P, and Turnbull LW (2005). Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91(1), 1-10.
26. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, and Schild HH (1999). Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211(1), 101-110.
27. Jensen LR, Berge K, Bathen TF, Wergedahl H, Schonberg SA, Bofin A, Berge RK, and Gribbestad IS (2007). Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI. Cancer Biol Ther 6(11), 1810-1816.
28. Mayr NA, Yuh WT, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, et al. (2000). Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12(6), 1027-1033.
29. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, and Gribbestad IS (2006). Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 19(1), 30-40.
30. Smyth GK (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article 3.
31. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57, 289-300.
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43), 15545-15550.
33. Kanehisa M and Goto S (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28(1), 27-30.
34. Kanehisa M, Goto S, Hattori M, oki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, and Hirakawa M (2006). From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34(database issue), D354-D357.
35. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, et al. (2008). KEGG for linking genomes to life and the environment. Nucleic Acids Res 36(database issue), D480-D484.
36. Eliyahu G, Kreizman T, and Degani H (2007). Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 120(8), 1721-1730.
37. Gidskehaug L, Anderssen E, Flatberg A, and Alsberg BK (2007). A framework for significance analysis of gene expression data using dimension reduction methods. BMC Bioinformatics 8, 346-359.
38. Pasquier E, Honore S, and Braguer D (2006). Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat 9(1-2), 74-86.
39. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, and Tozer GM (2002). Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15(2), 89-98.
40. 1H-MRS evaluation of malignant and benign breast diseases. Breast 12(3), 179-182.
41. 31Pmagnetic resonance spectroscopy study. Cancer Res 61(20), 7536-7543.
42. Pafumi Y, Lairon D, de la Porte PL, Juhel C, Storch J, Hamosh M, and Armand M (2002). Mechanisms of inhibition of triacylglycerol hydrolysis by human gastric lipase. J Biol Chem 277(31), 28070-28079.
43. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med 5(11), 1323-1327.
44. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfor K, Kristensen GB, and Gribbestad IS (2007). Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7, 11-22.
45. Brancolini C, Bottega S, and Schneider C (1992). Gas2, a growth arrest-specific protein, is a component of the microfilament network system. J Cell Biol 117(6), 1251-1261.
46. Goriounov D, Leung CL, and Liem RK (2003). Protein products of human Gas2-related genes on chromosomes 17 and 22 (hGAR17 and hGAR22) associate with both microfilaments and microtubules. J Cell Sci 116(pt 6), 1045-1058.
47. 0. Proc Natl Acad Sci USA 90(7), 2945-2949.
48. Morse DL, Galons JP, Payne CM, Jennings DL, Day S, Xia G, and Gillies RJ (2007). MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 20(6), 602-614.
49. Osborne CK, Hobbs K, and Trent JM (1987). Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 9(2), 111-121.
50. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327), 818-821.
51. Cao XH, Wang AH, Wang CL, Mao DZ, Lu MF, Cui YQ, and Jiao RZ (2010). Surfactin induces apoptosis in human breast cancer MCF-7 cells through a ROS/JNK-mediatedmitochondrial/caspase pathway. Chem Biol Interact 183(3), 357-362.
52. Lee SC, Chan J, Clement MV, and Pervaiz S (2006). Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics 6(8), 2386-2394.
53. Razmara M, Srinivasula SM, Wang L, Poyet JL, Geddes BJ, DiStefano PS, Bertin J, and Alnemri ES (2002). CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem 277(16), 13952-13958.
54. Brancolini C, Benedetti M, and Schneider C (1995). Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases. EMBO J 14(21), 5179-5190.
55. Sgorbissa A, Benetti R, Marzinotto S, Schneider C, and Brancolini C (1999). Caspase-3 and caspase-7 but not caspase-6 cleave Gas2 in vitro: implications for microfilament reorganization during apoptosis. J Cell Sci 112(pt 23), 4475-4482.
56. Pollok S and Grosse F (2007). Cdc45 degradation during differentiation and apoptosis. Biochem Biophys Res Commun 362(4), 910-915.
57. Pollok S, Bauerschmidt C, Sanger J, Nasheuer HP, and Grosse F (2007). Human Cdc45 is a proliferation-associated antigen. FEBS J 274(14), 3669-3684.
58. Gillingham AK, Pfeifer AC, and Munro S (2002). CASP, the alternatively spliced product of the gene encoding the CCAAT-displacement protein transcription factor, is a Golgi membrane protein related to giantin. Mol Biol Cell 13(11), 3761-3774.
59. Maag RS, Mancini M, Rosen A, and Machamer CE (2005). Caspase-resistant Golgin-160 disrupts apoptosis induced by secretory pathway stress and ligation of death receptors. Mol Biol Cell 16(6), 3019-3027.
60. Lee YM, Lee S, Lee E, Shin H, Hahn H, Choi W, and Kim W (2001). Human kinesin superfamily member 4 is dominantly localized in the nuclear matrix and is associated with chromosomes during mitosis. Biochem J 360(pt 3), 549-556.
61. Rosing M, Ossendorf E, Rak A, and Barnekow A (2007). Giantin interacts with both the small GTPase Rab6 and Rab1. Exp Cell Res 313(11), 2318-2325.
62. Guimaraes DP, Oliveira IM, de ME, Paiva GR, Souza DM, Barnas C, Olmedo DB, Pinto CE, Faria PA, De Moura Gallo CV, et al. (2009). Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 124(2), 272-279.
63. Malik NM, Moore GB, Kaur R, Liu YL, Wood SL, Morrow RW, Sanger GJ, and Andrews PL (2008). Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia. Regul Pept 148(1-3), 33-38.
64. Wagner K, Hemminki K, Grzybowska E, Klaes R, Burwinkel B, Bugert P, Schmutzler RK, Wappenschmidt B, Butkiewicz D, Pamula J, et al. (2006). Polymorphisms in genes involved in GH1 release and their association with breast cancer risk. Carcinogenesis 27(9), 1867-1875.
65. Wieland I, Sell C, Weidle UH, and Wieacker P (2004). Ectopic expression of DICE1 suppresses tumor cell growth. Oncol Rep 12(2), 207-211.
66. Wieland I, Ropke A, Stumm M, Sell C, Weidle UH, and Wieacker PF (2001). Molecular characterization of the DICE1 (DDX26) tumor suppressor gene in lung carcinoma cells. Oncol Res 12(11-12), 491-500.
67. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, et al. (2007). Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67(7), 3074-3084.